Telix Pharmaceuticals Limited Reports Qtrly Group Revenue Of $245 Million
Oct 21 (Reuters) - Telix Pharmaceuticals Limited TLX.AX:
QTRLY GROUP REVENUE OF US$245 MILLION
REAFFIRMED THAT FY 2026 REVENUE AND OTHER INCOME IS EXPECTED TO BE IN EXCESS OF US$1 BILLION
REVENUE TRACKING IN LINE WITH UPPER END OF FY 2026 GUIDANCE OF US$950 MILLION TO US$970 MILLION PLUS US$40 MILLION OF OTHER INCOME
REVISES FY 2026 RESEARCH AND DEVELOPMENT EXPENDITURE GUIDANCE RANGE TO US$240 MILLION TO US$260 MILLION
Further company coverage: TLX.AX